Results 151 to 160 of about 7,581 (239)

Global Antimicrobial Stewardship: Challenges and Successes from Frontline Stewards [PDF]

, 2015
Debra A. Goff, Michael J. Rybak
core   +1 more source

Landscape of resistance to ceftolozane/tazobactam and ceftazidime/avibactam in strains of Pseudomonas aeruginosa: a genomic approach in strains without selection pressure in a tertiary-care paediatric hospital in Mexico. [PDF]

BMC Infect Dis
A Méndez HE, Merida-Vieyra J, Aparicio-Ozores G, Hernández-Durán M, Méndez-Tenorio A, Tapia-Reyes A, Bautista-Hernandez R, Juárez-Hinojos D, Aquino-Andrade A.   +8 more
europepmc   +1 more source

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa

, 2022
María José Contreras-Gómez, José R W Martínez, Lina Rivas, Roberto Riquelme-Neira, Juan A. Ugalde, Aniela Wozniak, Patricia García, José M. Munita, Jorge Olivares‐Pacheco, Manuel Alcalde‐Rico   +9 more
openalex   +1 more source

Comparative in vitro Activities of Ceftazidime–Avibactam and Ceftolozane-tazobactam Against Characterized β-Lactamase-producing Pseudomonas aeruginosa [PDF]

, 2017
Lynn-Yao Lin, McClain Vail, Dmitri Debabov, Ian A. Critchley   +3 more
openalex   +1 more source

Ceftazidime-Induced Overexpression of MexJK-OprM Confers Resistance to Ceftolozane/Tazobactam in an Isolate of <i>Pseudomonas aeruginosa</i>. [PDF]

Infect Drug Resist
Sato T, Tamura M, Kaimori K, Okumura F, Ikejima S, Nakai H, Kawamura M, Fujimura S.   +7 more
europepmc   +1 more source

Targeting <i>Pseudomonas aeruginosa</i> resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion. [PDF]

Antimicrob Agents Chemother
Cojutti PG, Pai MP, Gatti M, Rinaldi M, Tonetti T, Siniscalchi A, Viale P, Pea F.   +7 more
europepmc   +1 more source

Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water

, 2017
Kevin A. Meyer, Maressa Santarossa, Larry H. Danziger, Eric Wenzler   +3 more
openalex   +2 more sources

1670. Activity of Ceftolozane/Tazobactam and Comparators Against Clinical MDR and DTR Pseudomonas aeruginosa isolates – SMART United States 2018-2020

, 2022
Sibylle Lob, Meredith Hackel, Fakhar Siddiqui, Karri A. Bauer, C Andrew DeRyke, Katherine Young, Mary Motyl, Daniel F. Sahm   +7 more
openalex   +1 more source

Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales? [PDF]

Antimicrob Agents Chemother
Pai MP, Cojutti PG, Gatti M, Rinaldi M, Tonetti T, Siniscalchi A, Viale P, Pea F.   +7 more
europepmc   +1 more source

Pharmacokinetic/Pharmacodynamic of ceftolozane/tazobactam in critically ill patients receiving extracorporeal membrane oxygenation (ECMO): a retrospective cohort analysis. [PDF]

Crit Care
Coppens A, Gautier M, Zahr N, Junot H, Rached B, Levy D, Saura O, Chommeloux J, Hekimian G, Schmidt M, Combes A, Bleibtreu A, Luyt CE.   +12 more
europepmc   +1 more source